No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 16.4x · 10Y median 12.2x · 60th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 21
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:07:58.758Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T21:07:58.758Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T21:07:58.758Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T21:07:58.758Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T21:07:58.758Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for OmniAb, Inc. (OABI) stock was $4.35 as of Oct 6, 2026, 4:00 PM EDT, down 11.59% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +200.3% · 3-year avg -1.3%/yr · 5-year avg -13.2%/yr
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery.
Biotechnology · EmeryVille, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.12
Revenue Est.
$3.43M
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.13
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OABI | $630.63M | $4.35 | -11.59% | +200.25% | -13.17% | N/A | N/A |
| 2PRME | $632.16M | $3.50 | +9.03% | -49.04% | N/A | N/A | vs OABI |
| 3ZVRA | $634.30M | $10.73 | +0.28% | +9.69% | +3.75% | -17.34% | vs OABI |
| 4AURA | $638.20M | $6.17 | -0.80% | +2.80% | N/A | N/A | vs OABI |
| 5SOPH | $619.15M | $7.38 | -10.00% | +85.81% | -13.62% | N/A | vs OABI |
| 6CLYM | $611.57M | $10.68 | -3.35% | +453.52% | N/A | N/A | vs OABI |
N/A
$13.41M
vs Estimate
$4.69M
Consensus Rating
Based on 5 analysts
Average Price Target
$8.40
+93.1% upside
Low
$5.00
Current
$4.35
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.12 | $-0.11 | $-0.10 | 3 |
| Quarter ending Dec 2026 | $-0.14 | $-0.13 | $-0.12 | 3 |
| Quarter ending Mar 2027 | $-0.13 | $-0.10 | $-0.08 | 1 |
| Quarter ending Jun 2027 | $-0.12 | $-0.10 | $-0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.37 | $-0.36 | $-0.35 | 4 |
| FY 2027 | $-0.33 | $-0.28 | $-0.23 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $3.30M | $3.43M | $3.55M | 5 |
| Quarter ending Dec 2026 | $3.50M | $3.84M | $4.44M | 5 |
| Quarter ending Mar 2027 | $5.95M | $6.99M | $8.52M | 4 |
| Quarter ending Jun 2027 | $6.67M | $7.84M | $9.56M | 4 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $34.53M | $34.96M | $35.63M | 5 |
| FY 2027 | $40.44M | $43.49M | $45.42M | 5 |
